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Abstract 
Primary effusion lymphoma (PEL) is a subset of large B cell lymphomas and has been mostly 
associated with human immunodeficiency virus infection. Rare cases have been reported in 
organ  transplant  recipients  and  chronic  hepatitis  C  patients.  It  typically  presents  as  an 
effusion in the pleural and pericardial spaces but rarely disseminates. However, involvement 
of the gastrointestinal tract, lymph nodes and bone marrow has been reported. Diagnosis is 
based  on  characteristic  clinical,  histopathological  and  immunohistochemical  features.  We 
present a case with a right atrial mass which tested positive for human herpes virus 8 (HHV-
8), CD20, CD30 and lambda light chains and negative for CD138, kappa light chain, PAX5, 
Epstein-Barr virus, latent membrane protein 1, CD2, CD3, CD8 and CD56. Bilateral pleural 
effusions and pericardial effusions were noted which tested positive for HHV-8, CD30 and 
CD45. The patient responded well to the R-EPOCH regimen with complete resolution of the 
effusions  and  a  significant  decrease  in  the  size  of  the  right  atrial  mass.  This  case  report 
illustrates the atypical manifestation of PEL as a right atrial mass. 
Introduction 
Primary effusion lymphoma (PEL) is a subset of non-Hodgkin’s lymphoma (NHL) and 
was first described in 1989 [1]. This entity was noted in human immunodeficiency virus  
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(HIV) patients, especially after NHL in patients with HIV had been determined to be an AIDS-
defining illness [2]. A malignant lymphoblastic effusion when associated with human herpes 
virus  8  (HHV-8)  infections  is  defined  as  PEL.  Most  of  these  affected  patients  are  also 
coinfected with Epstein-Barr virus (EBV). HHV-8 is endemic in sub-Saharan Africa and the 
Mediterranean region of the world [3]. Latency-associated nuclear antigen-1 (LANA-1) is a 
gene product of HHV-8, which is essential for viral DNA maintenance during replication. This 
protein  binds  to  the  p53  and  retinoblastoma  genes  and  inhibits  tumor  suppression  by 
impairing apoptosis [4]. Detection of LANA-1 by immunohistochemistry is considered the 
standard assay for confirming HHV-8 infection. The post-germinal B cells are considered the 
cells of origin for PEL [5]. PEL cells exhibit markers characteristic of plasma cells (CD138) 
and lymphocyte activation (CD30, CD38, CD71 and HLA-DR) but typical B cell and T cell 
markers are absent (CD19, CD20, CD79a, CD3, CD4 and CD8) [6, 7]. However, no chromoso-
mal  abnormalities  in terms  of translocations  and  abnormal  chromosomal  numbers have 
been detected [8]. PEL clinically manifests as a mass effect caused by the accumulation of 
fluid  laden  with  malignant  cells  in  body  cavities.  In  the  initial  presentation,  it  is  rarely 
detected beyond the pleural, pericardial and peritoneal surfaces. Extracavitary presentations 
have  been  reported,  principally  involving  the  gastrointestinal  tract  [9,  10].  In  this  case 
report, we present the clinical course of PEL in a patient with HIV who was found to have a 
right atrial mass in addition to pleural and pericardial effusions. This case is unique not only 
for its presentation as a right atrial mass but also for its favorable response to chemothera-
py. 
Case Presentation 
A 35-year-old Hispanic male with AIDS without prior opportunistic infections who was 
recently started  on antiretroviral therapy was  referred  from an outside hospital for the 
management  of  pericardial  and  bilateral  pleural  effusions.  One  month  earlier,  he  had 
presented  to  the  same  hospital  with  intermittent  fevers,  progressive  weakness  and  20-
pound  weight  loss.  Evaluation  during  that  admission  was  significant  for  generalized 
lymphadenopathy  and  thrombocytopenia  of  30,000/mm3.  A  computed  tomography  (CT) 
scan of the chest revealed a right atrial mass and mediastinal lymphadenopathy. His CD4 and 
viral load were 156 and 4 million copies, respectively. Bone marrow and left inguinal lymph 
node biopsies were nondiagnostic. He was discharged home on bactrim, truvada, ritonavir 
and darunavir. During his second hospitalization, he presented with syncope with no other 
localizing symptoms. On examination, he was in mild discomfort but otherwise afebrile and 
hemodynamically stable, with distant heart sounds and decreased air entry at the bases. A 
CT scan showed mediastinal adenopathy, bilateral pleural effusions, a pericardial effusion 
and a right atrial mass (fig. 1a). A cardiac echocardiogram showed a right atrial mass and a 
large pericardial effusion with tamponade physiology (fig. 1c). Thoracentesis of the right 
pleural  effusion  showed  a  lymphocytic  predominant  exudative  effusion.  Therapeutic 
pericardiocentesis  with  removal  of  560  ml  bloody  fluid  was  performed.  Fluid  cytology 
showed large lymphoblastic cells with a positive immunohistochemistry staining for HHV-8, 
CD30 and CD45. Staining for EBV, B and T cell markers was negative. The biopsy of the right 
atrial mass via transvenous route showed large lymphoblastic cells with positive staining for 
HHV-8, CD20, CD30 and lambda light chains (fig. 2a, b). Staining for CD138, kappa light 
chain,  PAX5,  EBV,  latent  membrane  protein  1  (LMP1),  CD2,  CD3,  CD8  and  CD56  was 
negative.  A  diagnosis  of  PEL  with  extracavitary  involvement  was  made  based  on  the 
presence  of  lymphoblastic  cells  and  immunohistochemical  staining.  The  patient  was  
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continued on antiretroviral therapy, started on the R-EPOCH regimen as an inpatient and 
discharged home with outpatient follow-up appointments to oncology and infectious disease 
clinics.  Subsequent  imaging  showed  resolution  of the  pleural  effusions  and  a significant 
decrease in the size of the right atrial mass (fig. 1b, d). 
Discussion 
PEL is a rare entity mostly described in patients infected with HIV. It accounts for 1–4% 
of AIDS-related lymphomas [7]. Effective treatment with highly active retroviral treatment 
has contributed to the decrease in the incidence of NHL. Very rarely, PEL has been reported 
in patients with organ transplant recipients and chronic hepatitis C virus infection [11–13]. 
It  is  a  subtype  of  diffuse  large  B  cell  lymphoma  with  a  unique  constellation  of  clinical, 
morphologic, immunophenotypic and molecular characteristics. There is no clear association 
with  the  CD4  count  and  viral  load  in  HIV-infected  patients  [14,  15].  HHV-8  has  been 
implicated in the pathogenesis of PEL [16, 17]. It predominantly affects males [14] and is 
characterized by a symptomatic serous effusion with involvement of the pleura (60–90%) 
and  pericardium  (30%)  causing  dyspnea,  the  peritoneum  (30–60%)  causing  abdominal 
discomfort and distension, joint spaces causing joint swelling and, rarely, the meninges [14]. 
Chest roentgenograms typically show pleural and pericardial thickening with an effusion in 
the absence of parenchymal abnormalities, masses or mediastinal enlargement [18, 19]. It 
rarely disseminates [14] but can present as solid tumors involving the gastrointestinal tract, 
lymph nodes and  bone marrow. Due to its unique liquid phase pattern of growth, fluid 
cytology is usually positive for malignant cells [16]. It is characterized by large multinucleat-
ed and multilobated cells with prominent nucleoli and abundant deep basophilic cytoplasm 
containing small clear vacuoles [11]. Immunohistochemical staining is positive for plasma 
cell markers (CD45, CD30, CD38, CD71, and CD138) but negative for B cell (CD19, CD20 and 
CD79a) and T cell (CD3, CD4 and CD8) markers. HHV-8 positivity (LANA-1) in the nuclei of 
malignant cells is important for clinching the diagnosis. Despite frequent coinfection with 
EBV, staining for LMP1 is negative [20]. 
Since PEL is a rare disease, treatment options are not well defined. There are no pro-
spective  trials  and  only  a  few  retrospective  treatment  series  are  currently  known.  The 
median survival without treatment is 2–3 months [21] and increases to about 6 months with 
treatment [22]. Different chemotherapy regimens have been used to treat this condition 
(CHOP, hyper-CVAD and rituximab) [7, 23]. High-dose chemotherapy followed by hemato-
poietic stem cell transplantation has generated mixed results and these data are mostly from 
case reports [24, 25]. In patients infected with HIV, a combination of antiretroviral therapy 
with  chemotherapy  has  superior  response  than  either  modality  used  alone  [14,  23]. 
Radiation  therapy  can  be  used  for  palliation  in  patients  who  are  not  candidates  for 
chemotherapy. Chemotherapy has been used with some success in HIV-negative patients. 
Cytology and biopsy of the pericardial effusion and right atrial mass in our patient were 
positive  for  PEL.  He  had  significant  mediastinal  lymphadenopathy  and  bilateral  pleural 
effusions, which we thought were likely due to PEL. His mediastinal lymph nodes were not 
sampled  and  the  pleural  fluid  was  not  sent  for  flow  cytometry.  Immunohistochemical 
staining of his right atrial mass biopsy was positive for HHV-8 and plasma cell markers; 
however, the cells were positive for B (CD20) and T (CD4) cell markers as well. To our 
knowledge, there has been only one case report of PEL presenting as intracardiac mass, and 
the patient responded favorably to chemotherapy [26]. This is probably one of the few cases 
of PEL with both cavitary and extracavitary involvements. Findings of an intracardiac mass  
Case Rep Oncol 2013;6:114–118 
DOI: 10.1159/000346838 
 
© 2013 S. Karger AG, Basel 
www.karger.com/cro 
Marak et al.: Extracavitary Manifestation of Primary Effusion Lymphoma as a Right Atrial 
Mass   
 
117 
in conjunction with pericardial and probably pleural and mediastinal lymph node involve-
ment, cell markers positive for plasma cells, and B and T cells altogether make our patient a 
unique case of PEL occurring in HIV infection. 
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Fig. 1.  a  A  chest  CT  scan  with  contrast  showing  a  right  atrial  mass,  a  large  pericardial  effusion  and 
bilateral pleural effusions. b A chest CT scan showing complete resolution of the bilateral pleural effusions 
3  weeks  after  the  first  dose  of  combination  chemotherapy.  c  An  echocardiogram  showing  a  large 
pericardial effusion with a large right atrial mass. d An echocardiogram showing complete resolution of 
the pericardial effusion and a significant decrease in the size of the right atrial mass 3 weeks after the first 
cycle of combination chemotherapy. 
 
 
 
Fig. 2. a The hematoxylin and eosin-stained section shows a relatively monomorphous sheet of medium-
sized  atypical  lymphocytes  with  round  nuclei,  fine  to  slightly  vesicular  chromatin,  one  or  several 
prominent  nucleoli  and  a  moderate  amount  of  slightly  vacuolated  pink  cytoplasm.  Mitotic  activity  is 
conspicuous  (blue  arrow).  There  are  scattered  necrotic  and  apoptotic  cells  (black  arrow).  b  Positive 
nuclear staining for HHV-8 by immunohistochemistry (some examples of positive nuclei are marked by 
black arrows). c Cytoplasmic staining for the B cell marker CD20. 
 